Chemotherapy is the most common treatment for leukemia across nearly all types and age groups. It remains the backbone of leukemia care, though the specific drugs, intensity, and duration vary dramatically depending on whether the leukemia is acute or chronic, and whether it affects lymphoid or myeloid cells. Many patients also receive targeted therapy, immunotherapy, or stem cell transplants alongside or after chemotherapy, but chemo is typically where treatment begins.
Why Chemotherapy Is the Standard Starting Point
Leukemia is a cancer of blood-forming cells, which means it doesn’t form a solid tumor that a surgeon can remove. The abnormal cells circulate through your bloodstream and bone marrow, so treatment needs to reach your entire body. Chemotherapy drugs travel through the blood and kill rapidly dividing cells wherever they are, making chemo uniquely suited to a cancer that’s already widespread by the time it’s diagnosed.
For acute leukemias, which progress quickly, chemotherapy is almost always the first treatment. The initial phase, called induction, aims to destroy enough leukemia cells that they become undetectable in blood tests and bone marrow biopsies. This is called remission. Induction chemotherapy for acute leukemia typically requires a hospital stay of several weeks because the drugs temporarily wipe out healthy blood cells along with cancerous ones, leaving you vulnerable to infections and bleeding until your bone marrow recovers.
For chronic leukemias, which grow more slowly, chemotherapy may still be used but is increasingly being replaced or combined with targeted therapies. Some patients with chronic lymphocytic leukemia (CLL), for example, may not need any treatment for years after diagnosis if the disease is progressing slowly, an approach called watchful waiting.
How Treatment Differs by Leukemia Type
Acute Lymphoblastic Leukemia (ALL)
ALL is the most common childhood cancer, and chemotherapy is its primary treatment. Treatment usually unfolds in three phases over two to three years. Induction lasts about a month and achieves remission in roughly 95% of children and around 80% of adults. After that, consolidation therapy uses different drug combinations to eliminate any remaining leukemia cells. Finally, maintenance therapy involves lower doses of chemo taken at home, often as pills, for one to two years to prevent relapse.
Because ALL can spread to the brain and spinal cord, patients also receive chemotherapy injected directly into the spinal fluid. This is called intrathecal chemotherapy and is a routine part of ALL treatment, not a sign that the cancer has spread to those areas.
Acute Myeloid Leukemia (AML)
AML is more common in adults and tends to be more aggressive. Induction chemotherapy is intense, typically involving a combination of drugs given over seven to ten days in the hospital. About 60% to 70% of adults under 60 achieve remission after induction. The challenge with AML is preventing relapse: without additional treatment, most patients relapse within months. Consolidation therapy with additional chemotherapy cycles or a stem cell transplant follows to reduce that risk.
A notable exception exists for a subtype called acute promyelocytic leukemia (APL). This form responds remarkably well to a combination of a vitamin A derivative and arsenic-based therapy, achieving cure rates above 90% often without traditional chemotherapy.
Chronic Myeloid Leukemia (CML)
CML treatment was revolutionized in the early 2000s by targeted therapy drugs called tyrosine kinase inhibitors. These pills block the specific protein that drives CML cell growth. Before these drugs existed, the median survival for CML was three to five years. Now, most patients on targeted therapy have a near-normal life expectancy. Traditional chemotherapy plays a minimal role in CML today, making it the major exception to chemo being the go-to treatment.
Chronic Lymphocytic Leukemia (CLL)
CLL, the most common leukemia in adults in Western countries, has also shifted away from chemotherapy-first approaches. Targeted therapies that block specific survival signals in CLL cells have become preferred for most patients. However, some treatment plans still combine chemotherapy with an antibody-based immunotherapy, particularly for younger, physically fit patients. Many people with early-stage CLL live for years without needing any treatment at all.
What Chemotherapy Actually Feels Like
The experience of leukemia chemotherapy depends heavily on the intensity. For acute leukemias, the initial hospital-based treatment is the hardest part. You can expect significant fatigue, nausea (managed with anti-nausea medications that have improved dramatically), mouth sores, hair loss, and a period of very low blood counts that requires close monitoring. Most patients spend three to five weeks in the hospital during induction for acute leukemias, with frequent blood transfusions and antibiotics to manage the temporary immune suppression.
Later phases of treatment are generally more manageable. Maintenance chemotherapy for ALL, for instance, involves pills and occasional clinic visits that allow most patients to return to school or work. Outpatient consolidation cycles for AML involve shorter hospital stays with recovery periods at home between rounds.
Side effects are real but temporary for most patients. Hair typically regrows within a few months of finishing treatment. Nausea is usually controllable with medications. The fatigue can linger for weeks to months after treatment ends but gradually improves. Long-term side effects, including a small increased risk of heart problems or secondary cancers years later, depend on the specific drugs used and are something your treatment team factors into planning.
Treatments Used Alongside or After Chemo
Chemotherapy is rarely the only tool used. Several other treatments play important roles depending on the situation.
- Stem cell transplant: For patients with high-risk or relapsed leukemia, a transplant replaces diseased bone marrow with healthy donor cells. This requires very high-dose chemotherapy (and sometimes radiation) first to destroy the existing marrow. Transplants carry significant risks, including graft-versus-host disease, where donor cells attack the patient’s body, but they offer the best chance of cure for certain leukemia subtypes.
- Targeted therapy: These drugs attack specific molecular features of leukemia cells. Beyond the CML drugs mentioned above, targeted therapies now exist for certain genetic mutations found in AML and for specific proteins on CLL cells. They tend to cause fewer side effects than traditional chemotherapy because they’re more selective about which cells they affect.
- Immunotherapy: This category includes antibody drugs that flag leukemia cells for destruction by your immune system, as well as CAR-T cell therapy, where your own immune cells are genetically modified in a lab to recognize and kill leukemia cells. CAR-T therapy has shown remarkable results for ALL that has relapsed after initial treatment, achieving remission in cases where other options had failed.
- Radiation therapy: Less commonly used in leukemia than in solid tumors, radiation may be directed at the brain or spleen in specific situations, or used as part of preparation for a stem cell transplant.
How Cure Rates Have Changed
Leukemia outcomes have improved substantially over the past few decades. Childhood ALL now has a five-year survival rate above 90%, making it one of the most curable cancers. CML went from a near-certain death sentence to a manageable chronic condition for most patients. Adult AML remains more challenging, with five-year survival rates around 30% overall, though younger patients and those with favorable genetic profiles do significantly better.
The trend across all leukemia types is toward more personalized treatment. Genetic testing of leukemia cells at diagnosis now helps determine which patients need aggressive therapy and which can be treated with less intensive approaches. This means two people with the same type of leukemia may receive very different treatment plans based on the specific mutations driving their disease, their age, and their overall health. Chemotherapy remains central to most of these plans, but it’s increasingly tailored and combined with newer therapies to improve both survival and quality of life during treatment.